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CObjectives: Hyperphosphatemia is a common and harmful condition
in patients with chronic kidney disease (CKD). We determined the cost-
effectiveness of the noncalcium-based phosphate binder lanthanum
carbonate (LC) as second-line treatment of hyperphosphatemia after
therapy failure with calcium-based binders (CB). Methods: Two CKD
populations were modeled: 1) predialysis CKD patients and 2) incident
dialysis patients. Patients not responding to CB with a serum phos-
phate (SP) level 5.5 mg/dl received a trial with LC. Patients not re-
sponding to LC (SP 4.6 mg/dl) returned to CB treatment. Patient-level
data were obtained from clinical trials in predialysis and dialysis. Time-
dependent, life-long Markov models (discounting at 3.5% annually)
were developed, using a UK National Health Service perspective.
Results: The health gains with second-line LC treatment compared to
CB treatment were 44 and 56 quality-adjusted life-years (QALYs) for the
predialysis and incident dialysis populations, respectively. Second-line
LC was a cost-saving strategy in the predialysis population because of O
idem
gen,
al So
oi:10.1016/j.jval.2011.05.005he cost-savings of delayed CKD progression. Second-line LC was cost-
ffective at £6900 (90% probability interval: £5800–£8300) per QALY
ained in the dialysis population. Results were robust to plausible vari-
tions in other model parameters; inclusion of future unrelated dialy-
is costs had a large influence on cost-effectiveness estimates.
onclusions: Second-line treatment with LC is associated with con-
iderable clinical benefits and good value for money in CKD, irrespec-
ive of dialysis status. These results support Kidney Disease Outcomes
uality Initiative guidelines to treat CKD patients with hyperphos-
hatemia irrespective of dialysis status.
eywords: chronic kidney disease, cost-effectiveness, end-stage re-
al disease, hyperphosphatemia, lanthanum carbonate, phosphate
inders.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Hyperphosphatemia is an electrolyte disturbance characterized by an
excess of serum phosphorus in the blood. It is a common and harmful
condition in patients with chronic kidney disease (CKD), irrespective of
dialysis status [1] CKD is a continuous process [2], and deregulation of
serum phosphate (SP) levels can occur at any point in this process [3].
Increased phosphate levels are independently associated with in-
creased morbidity and mortality in CKD patients on dialysis [4–6] and
predialysis across different CKD stages [7–9]. Treatment guidelines is-
sued by the Kidney Disease Outcomes Quality Initiative (K/DOQI) rec-
ommend that serum phosphate levels be maintained between 2.7 and
4.6 mg/dl in predialysis patients and between 3.5 and 5.5 mg/dl in dial-
ysis patients [10]. Unfortunately, less than half of the patients actually
achieve and sustain these targets [11].
The current first-line drug treatment of hyperphosphatemia in the
UnitedKingdom(UK),as inothercountries, incombinationwithdietary
restrictions [10], consists of calcium-based phosphate binders (CBs), in
particular, calcium carbonate and calcium acetate [12]. When calcium
agents are ineffective or inadequate, a strategy of dose escalation may
be inappropriate due to the increased risk of hypercalcemia [13], which
is linked to increased mortality [5,14]. K/DOQI guidelines recommend
* Address correspondence to: Stefan Vegter, Unit of PharmacoEp
niversity of Groningen, Antonius Deusinglaan 1, 9713 AV Gronin
E-mail: s.vegter@rug.nl.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.thattotaldaily intakeofcalcium,fromfoodanddrugtreatments,should
not exceed 2000 mg [10].
Lanthanum carbonate (LC) is a noncalcium-based phosphate bind-
ing agent licensed for hyperphosphatemic dialysis patients [15,16] and
recentlyalsoforCKDpatientsnotyetondialysis [17,18].Treatmentwith
LC after therapy failure with calcium carbonate treatment (i.e., second-
line LC treatment) was found to constitute good value-for-money in
dialysis patients [19]. The cost-effectiveness of LC in predialysis pa-
tients, however, has not been assessed. The goal of this study was to
determine the cost-effectiveness of second-line LC treatment of hyper-
phosphatemia in CKD patients before and after dialysis initiation, from
a UK National Health Service perspective.
Methods
Cost-effectiveness analysis
The cost-effectiveness of second-line LC treatment was as-
sessed for two CKD populations: 1) a predialysis CKD population
and 2) an incident dialysis population. Incremental cost-effec-
tiveness ratios (ICERs) were calculated as cost per life year
gained and cost per Quality Adjusted Life Year (QALY) gained. In
iology and PharmacoEconomics (PE2), Department of Pharmacy,
The Netherlands.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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853V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 5 2 – 8 5 8addition, the Net monetary benefit of LC over the comparator at
a decision-maker willingness-to-pay threshold of £30,000 per
QALY was evaluated [20]. Outcomes were rounded to the near-
est £100. The SP level upon which LC treatment is indicated for
use is 5.5 mg/dl [21]; the target SP level is 4.6 mg/dl for pre-
dialysis patients and 5.5 mg/dl for dialysis patients [10].
Choice of therapy initiation and evaluation of treatment re-
sponse were modeled according to these guidelines, shown in
Figure 1. Second-line LC treatment was considered for nonre-
sponders to CBs with SP levels exceeding 5.5 mg/dl. Response to
LC was evaluated within an 8-week drug trial period; patients
not achieving target SP levels during this drug trial were
switched back to calcium agents.
Economic model
A decision analytical structure was developed and linked to a
time-dependent Markov model [22]. Markovian modeling is a
ommonly used technique in decision analyses to handle the
omplexity of multiple interconnective, possible long-term con-
equences. The health states were predialysis, dialysis, and
eath; dialysis patients were not allowed to return to a predi-
lysis state. The number of patients in each health state was
etermined by yearly cycles; a half-cycle correction was applied
o account for the fact that events may occur at any point during
he year. For the cost-effectiveness analysis irrespective of di-
lysis status, the model was populated with cohorts of 1000
imulated predialysis patients; for the analysis in dialysis pa-
ients, cohorts of 1000 incident dialysis patients were used. An
verview of all model parameters is shown in Table 1. The
model structure and parameter assumptions were discussed
with two UK clinical experts who were consulted for this study.
Drug efficacy
Patient-level data were obtained from two randomized clinical
trials, one in predialysis patients (n  56 treated with LC) [17],
and one in dialysis patients (n 123 treated with LC and n 257
treated with CBs) [23]. Because of the relatively limited data
available for predialysis patients, the base-case drug efficacy for
predialysis patients was based on pooled data of predialysis and
dialysis patients. Only data from dialysis patients with compa-
rable baseline SP levels as predialysis patients, however, were
Fig. 1 – Decision analytical structure and Markov model (top
carbonate.used to calculate drug efficacy in predialysis. The assumptionthat the efficacy of drug intervention in dialysis patients with SP
levels comparable to those of predialysis patients is transfer-
able was verified as reasonable and appropriate by the clinical
experts consulted for this study. Long-term response to LC was
modeled using patient-level data [23] with a previously reported
method [19] and was assumed to be the same for predialysis and
dialysis patients.
Clinical efficacy and adverse events
Mortality rates according to patients’ SP level were derived from
epidemiological studies in 3490 predialysis patients [8] and 40,538
dialysis patients [5]. Baseline expected survival was estimated us-
ing long-term observational data for almost 28,000 predialysis pa-
tients [24] and more than 66,000 dialysis patients [25]. CKD pro-
gression rates were based on data for 4231 CKD stage 4 patients
[26]. The baseline survival and CKD progression rates were ad-
justed for patients’ average SP levels before applying SP-specific
relative risks [19].
In the trials used for this analysis, vomiting was significantly
increased with LC compared to CB in predialysis patients (4.0%)
[17] and dialysis patients (7.2%) [23]. Duration of vomiting was
estimated to be 7 days [19]; during this period, patients were as-
sumed to be prescribed an antiemetic drug (domperidone, 40 mg/
day).
Costs and utilities
A third-party payer (UK National Health Service) perspective
was adopted for cost estimates. Drug doses of lanthanum car-
bonate and calcium agents were based on the mean actual daily
dose from the trials in predialysis patients [17,27] and dialysis
atients [23]. Drug costs were based on the British National For-
ulary [28]. The costs of dialysis were based on a weighted
verage [29] of UK cost estimates for hemodialysis and perito-
neal dialysis [30]. Dialysis costs in added life-years as a conse-
quence of the more effective phosphate binder strategy were
classified as unrelated future costs because prolonged dialysis
care is exclusively related to the extended life of treated pa-
tients and not directly to the choice of phosphate binder [31,32].
Following previous pharmacoeconomic analyses, these future
unrelated dialysis costs were excluded from the base-case anal-
ysis but included in sensitivity analysis. All costs were updated
t corner). CB, calcium-based binder; LC, lanthanumrighto 2009 values. Quality of life (QoL) estimates were identified
s: 5.2
854 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 5 2 – 8 5 8using a recent systematic review [33]. Using a weighted average
of studies identified in this review, a QoL utility of 0.71 was used
for predialysis patients and 0.61 for dialysis patients [34,35]. A
utility decrement of 0.14 was assumed for a vomiting episode,
derived from a published study [36].
Sensitivity analysis
Parameter uncertainty was handled by performing a probabilis-
tic sensitivity analysis (PSA) [22]. In the PSA, joint parameter
uncertainty was handled by specifying a probability distribu-
tion for each of the parameters [22], shown in Table 1. For pa-
rameters based on patient-level data as well as literature
review, probability distributions as suggested by health eco-
nomics guidebooks were used [37]. No probability distribution
could be adopted for adverse event rates; therefore, a triangular
distribution was used. To explore the sensitivity of the results to
uncertainty in individual parameters, scenario analyses were
Table 1 – Model parameters.
Predialysis value
(95% CI)
Clinical pathways
Treatment initiation in mg/dl 5.5
Target level in mg/dl 4.6
Drug efficacy, %
First-line response rate to CB 45.6 (40.5–50
Second-line response rate to LC 18.8 (16.0–21
Long-term response to LC   0.55
  0.92
(0.46–0.
(0.78–1.
Mortality and CKD progression
Baseline yearly mortality 5.6% (5.2–5.9
RR of mortality by SP level, in mg/dl
2.5 0.95 (0.69–1.
2.5–3.0 1.00 (1.00–1.
3.0–3.5 1.15 (0.95–1.
3.5–4.0 1.32 (1.09–1.
4.0–4.5 1.34 (1.05–1.
4.5–5.0 1.83 (1.33–2.
5.0–5.5 1.90 (1.30–2.
5.5–6.0 1.90 (1.30–2.
6.0–7.0 1.90 (1.30–2.
7.0–8.0 1.90 (1.30–2.
8.0–9.0 190 (1.30–2.
9.0 1.90 (1.30–2.
Baseline yearly CKD progression 14.3% (13.6–15
RR CKD progression (per mg/dl in SP) 1.19 (1.10–1.
Quality of Life
Quality of life 0.71 (0.69–0.
Utility decrement vomiting 0.14 (0.08–0.
Adverse events
Increase of vomiting for LC, % 4.0 (3.0–5.0
Duration of vomiting in days 7 (5.3–8.8
Drug costs, £
Yearly drug price of LC 1198 (1047–1
8-wk LC trial 177 (153–20
Yearly drug price of CC 56 (29–83)
Yearly drug price of CA 40 (21–60)
Dialysis costs, £* NA
Discounting rate, % 3.5
CA, CC, CB, calcium-based binder; CI, confidence interval; CKD, chr
probabilistic sensitivity analysis; RR, relative risk; SP, serum phospha
* Weighted by prevalence of dialysis modalities (hemodialysis: 24.
peritoneal dialysis: 3.8%, continuous ambulatory peritoneal dialysiperformed using alternative literature sources and variations instructural pathway decisions. In one scenario, future unrelated
dialysis costs were included.
Time horizon and discounting
A lifelong model was adopted, following all patients until death or
a maximum follow-up of 40 years, with shorter time horizons ex-
plored in sensitivity analysis. Costs and health effects were dis-
counted at an annual rate of 3.5% in line with standard UK guid-
ance [20].
Statistics and software
Baseline characteristics were compared using the Student t test
or chi-square test, where appropriate. A P value of 0.05 was
considered statistically significant. The cost-effectiveness
model was developed and built in Excel; the PSA to calculate
Dialysis value (95% CI) PSA Ref.
5.5 [21]
5.5 [10]
62.2 (59.0–65.4) Binomial [23,27]
44.6 (40.0–48.5) Binomial [17,23]
  0.55
  0.92
(0.46–0.65)
(0.78–1.05)
Weibull [17,23]
  0.21
  0.87
(0.15–0.26)
(0.76–0.99)
Normal/Weibull [24,25]
1.00 (0.96–1.24) Normal [5,8]
1.00 (0.96–1.24)
1.00 (0.93–1.07)
1.00 (0.93–1.07)
1.00 (1.00–1.00)
1.00 (1.00–1.00)
1.07 (1.01–1.14)
1.00 (1.01–1.14)
1.25 (1.17–1.34)
1.43 (1.31–1.54)
1.67 (1.51–1.86)
2.02 (1.76–2.27)
NA Poisson [26]
NA Normal [26]
0.61 (0.57–0.65) Beta [34,35]
0.14 (0.08–0.20) Beta [36]
7.2 (5.4–9.0) Triangular [17,23]
7 (5.3–8.8) Triangular [19]
1540 (1454–1625) Log normal [28]
224 (212–235) Log normal [28]
85 (77–96) Log normal [28]
NA Log normal [28]
34,100 (28,120–42,230) Log normal [30]
3.5 [20]
kidney disease; LC, lanthanum carbonate; NA, not applicable; PSA,
ome hemodialysis: 1.1%, satellite hemodialysis: 18.6%, automated
%) [29]..9)
.6)
65)
05)
)
32)
00)
39)
61)
71)
51)
79)
79)
79)
79)
79)
79)
.0)
29)
73)
20)
)
)
347)
0)
onic
te.
4%, h90% probability intervals (PIs) was performed with the Excel
855V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 5 2 – 8 5 8add-on @RISK. Statistical tests and graphs were produced using
the statistical program R.
Results
Baseline characteristics
Age, sex, and baseline SP were similar between LC- and CB-treated
patients, both for predialysis and dialysis patients. Age and base-
line SP did not differ significantly between the predialysis patients
and the subset of SP-matched dialysis patients used for pooling;
there were, however, slightly more females in the predialysis pop-
ulation (50% vs. 36%, P  0.04).
Drug efficacy
In predialysis patients, first-line response rate to CBs was 45.6%.
Hence, in the simulated cohort of 1000 CKD predialysis patients,
544 patients (54.4%) did not achieve SP targets with first-line CB
treatment. In the LC strategy, 230 of these 544 nonresponders had
an SP level5.5 mg/dl and therefore received an 8-week trial of LC
treatment. Of these, 43 (18.8%) showed therapy response to LC, the
remaining 187 patients returned to CB treatment. On entering the
dialysis health state, the target SP treatment level recommended
by international guidelines changed from 4.6 mg/dl for predialy-
sis patients to 5.5 mg/dl in the dialysis population [10]. Because
of this change in target SP level, more patients treated with LC
were classified as therapy responders. An incremental 79 patients
responded to second-line LC treatment compared to CB after
reaching dialysis.
In the population of incident dialysis patients, the first-line CB
response rate was 62.2%. Thus, in the 1000 incident dialysis pa-
tient cohort, 378 patients (37.8%) did not achieve SP targets with
first-line CB treatment. In the LC strategy, 168 patients (44.4%)
showed therapy response to LC; the remaining 210 patients re-
turned to CB treatment. The total number of therapy responders in
the two CKD populations is presented in Table 2.
Health outcomes
Median survival of predialysis patients predicted by our model
was 6.5 years; the median survival of incident dialysis patients
was 3.5 years. The increase in therapy response with second-line
Table 2 – Cost-effectiveness of second-line LC treatment in
Pre
Therapy response
Additional LC responders in predialysis
Additional LC responders in dialysis
Total additional LC responders
Health effects
Life-years gained
Dialysis-free years gained
QALYs gained
Costs, £
Additional drug costs
Dialysis costs
Total costs
Cost-effectiveness
Cost per LY gained, £
Cost per QALY gained, £
Net monetary benefit, £*
LC, lanthanum carbonate; LY, life-year; NA, not applicable; PI, probab
* At a threshold willingness-to-pay of £30,000 per QALY.LC treatment resulted in additional life-years and QALYs in bothCKD populations (Table 2). In predialysis patients, 21.3 (15.4–28.2)
additional dialysis-free years were gained with second-line LC
treatment due to delayed CKD progression. The total clinical ben-
efit of second-line LC treatment was 44.1 QALYs (33.4–54.2) in the
predialysis population and 55.8 QALYs (42.6–72.3) in the dialysis
population.
Cost-effectiveness
For the predialysis patient population, second-line LC treatment
was a dominating strategy compared to only CB treatment (i.e.,
second-line LC resulted in cost-savings as well as clinical benefits).
Because SP levels influenced CKD progression in the model, im-
proved SP control with second-line LC treatment resulted in con-
siderable prevention and delay of end-stage renal disease. Indeed,
the cost savings in predialysis patients were mainly due to pre-
vented or delayed dialysis care costs. The net monetary benefit for
a willingness-to-pay of £30,000 per QALY gained was £1700 (90% PI
£1200–£2200). For the incident dialysis patient population, the
cost-effectiveness was £6900 per QALY (90% PI £5500– £8800 per
QALY), with a net monetary benefit of £1300 (90% PI £900–£1700),
shown in Table 2.
Sensitivity analyses
The results were robust to plausible variations in model parame-
ters, both in the predialysis population (Fig. 2) and in the dialysis
population (Fig. 3). Using alternative discounting rates or literature
sources for CKD progression [38,39] or varying the frequency of
adverse events did not influence the cost-effectiveness outcome.
Using an alternative source for dialysis mortality [4] increased the
incremental cost-effectiveness ratio (ICER) in the dialysis popula-
tion to £22,300 per QALY. Of note, not using pooled data for drug
efficacy in predialysis patients (i.e., using data of predialysis pa-
tients only) had no considerable influence on the cost-effective-
ness for LC in this population with an ICER of £1500 per QALY (90%
PI £900–£2300), Figure 2. Including unrelated future dialysis costs,
however, had a large influence on LC cost-effectiveness. When
unrelated future dialysis costs were included, the ICER increased
to £48,600 per QALY gained in the predialysis population and
ialysis and dialysis.
sis value (90% PI) Dialysis value (90% PI)
3 (34–53) NA
9 (69–89) 168 (151–185)
2 (109–135) 168 (151–185)
4 (53.6–85.9) 91.9 (70.7–117.8)
3 (15.4–28.2) NA
1 (34.1–54.2) 55.8 (42.6–72.3)
7 (333–451) 386 (338–446)
6 (1020–509) NA
9 (634 to 129) 386 (338–446)
ominating 4200 (3400–5300)
ominating 6900 (5500–8800)
0 (1200–2200) 1300 (900–1700)
interval; QALYs, quality-adjusted life-years.pred
dialy
4
7
12
69.
21.
44.
38
72
33
D
D
170
ility£63,000 per QALY gained in the dialysis population.
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Although the efficacy of calcium and noncalcium-based phos-
phate binders is similar in a treat-to-target setting [40,41], calcium
agents are less expensive and often prescribed as first-line ther-
apy. Noncalcium-based phosphate binders, such as lanthanum
carbonate and sevelamer, may be prescribed after therapy failure
or other contraindication for calcium agents. Our model demon-
strated that second-line use of LC was cost-effective irrespective
of dialysis status. In a 1000-predialysis patient cohort, a total of 70
life-years and 44 QALYs were gained by second-line LC use, as well
as 21 dialysis-free years. In addition, cost savings of £339 per pa-
tient were seen, resulting in second-line LC use dominating the
omparator strategy. In the 1000 incident dialysis patient cohort, a
otal of 92 life-years and 56 QALYs were gained by second-line LC
se and the ICER was £6900 per QALY, within the acceptable UK
hresholds of cost-effective treatments.
Fig. 2 – Sensitivity analysis in predFig. 3 – Sensitivity analysis in dialysis.One of the main cost-effectiveness drivers in our model was
the rate of CKD progression in predialysis patients. Dialysis costs
are high, and therefore delaying dialysis initiation can lead to large
cost savings. Indeed, earlier studies have found that treatments
that delay CKD progression are cost saving [42,43]. Improved SP
control with second-line LC treatment [26,38,39] resulted in con-
iderable prevention and delay of end-stage renal disease. By
onetizing these clinical benefits, our model predicted overall
ost savings for second-line LC treatment, despite the higher drug
osts of LC compared to calcium agents. In our model, the median
urvival of predialysis and dialysis patients was 6.5 and 3.5 years,
espectively. The external validity of our model is supported by
bservational data of 335 Canadian CKD predialysis patients (me-
ian survival of 6.4 years) [44] and more than 3000 Scottish inci-
ent dialysis patients (median survival of 3.2 years) [45].
The results were robust to plausible variations in model pa-
ameters, including discounting rate and data sources for CKD
sis. CKD, chronic kidney disease.QALY, quality-adjusted life-years.
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857V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 5 2 – 8 5 8progression and mortality. Unrelated future dialysis costs, how-
ever, had a large influence on the ICER. Unrelated future costs
were excluded from the base-case analysis. The inclusion or ex-
clusion of unrelated future costs is the topic of a long-standing and
as-of-yet unresolved discussion [31,32]; in fact, dialysis has been
enter stage in this discussion [46,47]. Our results add to this dis-
ussion by demonstrating, in sensitivity analysis, that positive
ost-effectiveness outcomes were largely dependent on the exclu-
ion of future unrelated costs.
This study, to the best of our knowledge, is the first to analyze
he cost-effectiveness of phosphate binders in CKD patients be-
ore dialysis initiation. A previous cost-effectiveness analysis in
ialysis patients reported an ICER of second-line LC of £25,000 per
ALY [19]. The previous analysis used data from a 1998 observa-
ional study of Block et al. [4]. In contrast, our model used a larger
(40,538 versus 6,407 patients), more recent (2004 vs. 1998), and
with longer follow-up (2.0 years vs. 1.5 years) study by the same
authors [5]. Several other model parameters were updated as well,
ncluding drug costs and QoL estimates.
Our model had some limitations. Data on LC and CB efficacy
were derived from 56 and 28 predialysis patients, respectively
[17,27]. Although a lack of data in predialysis also applies to other
noncalcium phosphate binders [48], we tried to overcome this lim-
itation by pooling predialysis patients with a subset of dialysis
patients. Dialysis patients with an SP level comparable to that of
predialysis patients were selected for pooling to reduce heteroge-
neity. Indeed, population characteristics between the two popula-
tions were found to be similar. Furthermore, sensitivity analysis
showed that results were similar when dialysis patients were ex-
cluded from the pooled data set. Therefore, the use of pooled effi-
cacy data enhanced the robustness of our results without biasing
the cost-effectiveness outcome. Another limitation of our study
was that in the predialysis population, the majority of LC-treated
patients were phosphate binder naive [17], thereby not accurately
modeling second-line LC treatment.
Several conservative model assumptions were made for this
analysis. Patients treated with noncalcium-based binders experi-
ence fewer hypercalcemic events compared to CB-treated patients
[49]. Hypercalcemia has been linked to increased mortality in di-
alysis [5,14] and predialysis [50,51]; a causal link between binder
hoice and mortality, however, was not confirmed in a recent
eta-analysis [49]. Therefore, we conservatively did not model
ny influence of hypercalcemic events in our analysis. LC reduces
ill burden compared to calcium agents, which has been associ-
ted with higher QoL and patient preference [52,53] and improved
rug compliance [53]. Quantitatively useful data for model inclu-
ion of these parameters were not available; therefore, we conser-
atively did not model any influence of pill burden on QoL or drug
fficacy. Finally, lowering SP reduces the risk of bone disease and
onfatal cardiovascular events, reflected by a decrease in hospi-
alizations [5,54]. This was not included in the model due to a lack
f available data.
In conclusion, the use of LC as second-line treatment for hy-
erphosphatemia after first-line use of CBs, results in considerable
ealth benefits and is cost-effective, using a UK National Health
ervice perspective, irrespective of dialysis status. The results of
his study strengthen K/DOQI recommendations to treat CKD pa-
ients with elevated serum phosphate levels irrespective of dialy-
is status [10]. Furthermore, our results suggest that second-line
reatment with LC after therapy failure with CBs may be consid-
red in CKD patients irrespective of dialysis status.
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